key: cord-0694403-nqn0c3au
authors: Verhoeven, Frank; Lepiller, Quentin; Hecquet, Sophie; Prati, Clément; Wendling, Daniel
title: Answer to Mungmunpuntipantip et al « SARS CoV-2 vaccine AND rituximab» Joint Bone Spine 2021;88:105281
date: 2021-10-01
journal: Joint Bone Spine
DOI: 10.1016/j.jbspin.2021.105283
sha: 8afe092cd0fe1a9210aea065acbb1b87a18df50b
doc_id: 694403
cord_uid: nqn0c3au

nan

We thank Professor Mungmunpuntipantip for his comment (1) . We agree that immunization against SARS CoV2 is achieved through both humoral and cellular immunity. Concerning humoral immunity, several data are available showing, as in our case, a decrease in the humoral response to vaccination (2) (3) . This element was expected. Recent studies suggested that specific T cell response after SARS-CoV-2 vaccination was still present in series of 11 and 46 patients treated with rituximab (4) (5) . However, scientific knowledge is quickly evolving and a very recent study, conducted on 96 patients, found an alteration in postvaccination cellular immunity (6) in patients treated with rituximab. Interestingly, the time since the last infusion was a prognostic factor for humoral and cellular vaccine response. The impact of Rituximab on the vaccine response to SARS CoV2 is unclear and our case shows that infection after vaccination can occur. In view of this, great caution should be taken in our patients.

SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20

B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study